McKesson acquires RxCrossroads from CVS Health

SAN FRANCISCO — McKesson on Monday announced that it has signed a definitive agreement to purchase RxCrossroads from CVS Health in a deal valued at $735 million. The acquisition is expected to close in the fourth quarter of fiscal 2018, subject to customary closing conditions, including necessary regulatory clearances.



“McKesson’s acquisition of RxCrossroads is another example of our continued focus on expanding and enhancing solutions for our biopharma manufacturer partners to deliver better patient support and better health outcomes,” stated John Hammergren, chairman and CEO, McKesson. “This investment will strengthen our existing best-in-class solutions, including hub services and patient assistance programs, while establishing new logistics services to plasma manufacturers, which allows us to serve biopharma companies of all sizes and throughout the product life cycle.”



According to the wholesaler, this acquisition will enhance McKesson’s existing commercialization solutions for manufacturers of branded, specialty, generic and biosimilar drugs, including comprehensive patient support (“hub”) services, custom pharmacy solutions and third-party logistics, allowing McKesson to grow its end-to-end offerings for manufacturers. In addition, the acquisition will add plasma logistics to McKesson’s manufacturer services, complementing the company’s established customer-facing plasma offerings.



Following the close of the transaction, RxCrossroads will become part of the company’s McKesson Specialty Health business.